The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with…

By F. Breedveld, M. Weisman, A. Kavanaugh, S. Cohen, K. Pavelka, R. V. van Vollenhoven, J. Sharp, John L. Perez, G. Spencer-Green. Arthritis & Rheumatism, 2006

1,908 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/4e569ce30c7d530460d742822e77e5d40c31c76a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. I. McInnes

In Rheumatology

1. Daniel Aletaha
2. J. Smolen
3. D. Tracey
4. I. McInnes
5. Lars Klareskog
6. J. Salfeld
7. P. Tak
8. E. Sasso

Citations in the corpus

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (2013, background): “It is rewarding to see that some of the items of the research agenda presented in 2010 (eg, items 2, 4, 6) 3 have already been partly or fully addressed and this, indeed, informed the current update.”
• Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study (2009, background): “7 years) and a comparable methotrexate dosing schedule, DAS28 remission rates at 12 months were 23% for adalimumab versus 21% for methotrexate monotherapy (not significant); however, a greater benefit could have been seen earlier in the treatment course.(17)”
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010, positive): “…this combination has greater effi cacy than monotherapy with most biological agents; this is well established for TNF inhibitors on the basis of respective comparative phase III trials 55 56 and for rituximab and tocilizumab on the basis of comparative phase II trials 58 59 (level 1b, grade A).”
• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “In the treatment of RA, combinations of TNF antagonists with low-dosage methotrexate have generally been more efficacious than either drug alone (Maini et al., 1998; Klareskog et al., 2004; Breedveld et al., 2006).”